Novo Nordisk
NVO
#77
Rank
NZ$380.85 B
Marketcap
NZ$86.09
Share price
-2.25%
Change (1 day)
-20.15%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2026 (TTM): NZ$7.35

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is NZ$7.35. In 2025 the company made an earnings per share (EPS) of NZ$6.08 an increase over its 2024 EPS that were of NZ$5.60.

EPS history for Novo Nordisk from 2016 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$7.3521.04%
2025NZ$6.088.48%
2024NZ$5.60
2016NZ$1.91

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.24-69.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.29 557.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$4.38-40.41%๐Ÿ‡ซ๐Ÿ‡ท France
Bristol-Myers Squibb
BMY
NZ$6.09-17.12%๐Ÿ‡บ๐Ÿ‡ธ USA